Researchers found that novel chemical modulators that prompted activation and amplification of normal, wild-type glucocerebrosidase, an enzyme encoded by the GBA1 gene that is associated with Parkinson's disease, enabled better neuronal cell function, as well as reduced cellular dysfunction among people with different Parkinson's types. The approach, described in Science Translational Medicine, may be used to treat various forms of Parkinson's with lower GCase enzyme activity, researchers concluded.
Study evaluates breakthrough treatment approach in Parkinson's
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.